Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Finch Therapeutics Group to similar businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Volatility & Risk
Finch Therapeutics Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group’s peers have a beta of 0.76, suggesting that their average stock price is 24% less volatile than the S&P 500.
22.7% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 53.2% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.8% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of recent ratings for Finch Therapeutics Group and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Finch Therapeutics Group||0||0||1||0||3.00|
|Finch Therapeutics Group Competitors||1657||5735||11373||210||2.53|
Finch Therapeutics Group currently has a consensus target price of $17.00, suggesting a potential upside of 645.61%. As a group, “Biological products, except diagnostic” companies have a potential upside of 115.78%. Given Finch Therapeutics Group’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Finch Therapeutics Group is more favorable than its peers.
This table compares Finch Therapeutics Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Finch Therapeutics Group||-448.35%||-33.13%||-30.11%|
|Finch Therapeutics Group Competitors||-4,587.78%||-67.40%||-30.70%|
Earnings and Valuation
This table compares Finch Therapeutics Group and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Finch Therapeutics Group||$18.53 million||-$58.16 million||-1.57|
|Finch Therapeutics Group Competitors||$773.46 million||$147.16 million||-0.23|
Finch Therapeutics Group’s peers have higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Finch Therapeutics Group beats its peers on 7 of the 13 factors compared.
Finch Therapeutics Group Company Profile (Get Rating)
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.